tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

IONS Stock Latest News

Ionis Pharmaceuticals: Buy Rating Affirmed Amid Promising Clinical Trial Results and Future Prospects
RatingsIonis Pharmaceuticals: Buy Rating Affirmed Amid Promising Clinical Trial Results and Future Prospects
10d ago
IONS
Cautious Optimism for Ionis Pharmaceuticals Amid Promising Olezarsen Data and Awaited CORE/CORE2 Insights
PremiumRatings
Cautious Optimism for Ionis Pharmaceuticals Amid Promising Olezarsen Data and Awaited CORE/CORE2 Insights
11d ago
IONS
Promising Phase 3 Results and Future Prospects of Tryngolza Drive Buy Rating for Ionis Pharmaceuticals
PremiumRatings
Promising Phase 3 Results and Future Prospects of Tryngolza Drive Buy Rating for Ionis Pharmaceuticals
11d ago
IONS
Ionis Pharmaceuticals’ Promising Future: Buy Rating Backed by Positive Phase 3 Study Results and Upcoming Milestones
PremiumRatings
Ionis Pharmaceuticals’ Promising Future: Buy Rating Backed by Positive Phase 3 Study Results and Upcoming Milestones
11d ago
IONS
Promising Clinical Trial Results and Market Potential Justify Buy Rating for Ionis Pharmaceuticals
PremiumRatings
Promising Clinical Trial Results and Market Potential Justify Buy Rating for Ionis Pharmaceuticals
12d ago
IONS
Ionis Pharmaceuticals: Hold Rating Amid Promising Yet Preliminary Clinical Trial Results
PremiumRatingsIonis Pharmaceuticals: Hold Rating Amid Promising Yet Preliminary Clinical Trial Results
12d ago
IONS
Ionis Pharmaceuticals Announces Positive Essence Study Results
Premium
Company Announcements
Ionis Pharmaceuticals Announces Positive Essence Study Results
12d ago
8K
IONS
Ionis Pharmaceuticals announces topline results from Essence study of olezarsen
Premium
The Fly
Ionis Pharmaceuticals announces topline results from Essence study of olezarsen
12d ago
IONS
Ionis Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating
PremiumRatings
Ionis Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating
29d ago
IONS
Ionis Pharmaceuticals price target raised to $50 from $45 at H.C. Wainwright
PremiumThe Fly
Ionis Pharmaceuticals price target raised to $50 from $45 at H.C. Wainwright
1M ago
IONS
Ionis Pharmaceuticals: Strong Buy Rating Backed by Robust Drug Performance and Strategic Market Expansion
PremiumRatings
Ionis Pharmaceuticals: Strong Buy Rating Backed by Robust Drug Performance and Strategic Market Expansion
1M ago
IONS
Ionis Pharmaceuticals price target lowered to $64 from $65 at Guggenheim
PremiumThe Fly
Ionis Pharmaceuticals price target lowered to $64 from $65 at Guggenheim
1M ago
IONS
Ionis Pharmaceuticals: Strong Q1 Performance and Future Growth Potential Drive Buy Rating
PremiumRatingsIonis Pharmaceuticals: Strong Q1 Performance and Future Growth Potential Drive Buy Rating
1M ago
IONS
Ionis Pharmaceuticals Reports Strong Q1 2025 Results
Premium
Company Announcements
Ionis Pharmaceuticals Reports Strong Q1 2025 Results
1M ago
IONS
Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges
Premium
Company Announcements
Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges
1M ago
IONS
Ionis Pharmaceuticals: Strong Financial Performance and Strategic Partnerships Justify Buy Rating Despite Adjusted Price Target
PremiumRatings
Ionis Pharmaceuticals: Strong Financial Performance and Strategic Partnerships Justify Buy Rating Despite Adjusted Price Target
1M ago
IONS
Ionis Pharmaceuticals: Strong Performance and Promising Pipeline Justify Buy Rating
PremiumRatings
Ionis Pharmaceuticals: Strong Performance and Promising Pipeline Justify Buy Rating
1M ago
IONS
Ionis Pharmaceuticals: Strong Q1 Performance and Promising Outlook Drive Buy Rating
PremiumRatings
Ionis Pharmaceuticals: Strong Q1 Performance and Promising Outlook Drive Buy Rating
1M ago
IONS
Ionis Pharmaceuticals ups FY25 revenue view to $725M-$750M from at least $600M
PremiumThe Fly
Ionis Pharmaceuticals ups FY25 revenue view to $725M-$750M from at least $600M
1M ago
IONS
Ionis Pharmaceuticals reports Q1 EPS (93c), consensus ($1.03)
PremiumThe FlyIonis Pharmaceuticals reports Q1 EPS (93c), consensus ($1.03)
1M ago
IONS
IONS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
IONS Earnings this Week: How Will it Perform?
1M ago
IONS
Ionis Pharmaceuticals’ Tryngolza: Promising Treatment for Severe Hypertriglyceridemia with Strong Market Potential
Premium
Ratings
Ionis Pharmaceuticals’ Tryngolza: Promising Treatment for Severe Hypertriglyceridemia with Strong Market Potential
2M ago
IONS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >